Participant Flow Module
The Participant Flow Module provides information about the flow of participants through each stage of the clinical trial. This includes pre-assignment details, recruitment information, and the types of units analyzed, helping researchers understand how participants move through the study.
Participant Flow Module path is as follows:
Study -> Results Section -> Participant Flow Module
Participant Flow Module
Ignite Creation Date:
2025-12-24 @ 2:30 PM
Ignite Modification Date:
2025-12-25 @ 1:04 PM
NCT ID:
NCT04074759
Pre Assignment Details:
Participants received escalating doses of FTP155 until the recommended dose (RD) was established in Phase 1a monotherapy. Phase 1b monotherapy involved dividing participants into 4 tumor-specific cohorts, treated at the RD. In Phase 1a combination therapy, participants with non-small cell lung cancer were split into 3 cohorts and given FTP155 below the RD with Pembrolizumab. Both Phase 1b monotherapy and Phase 1a combination were initiated but not completed due to the study's closure.
Recruitment Details:
Participants with advanced solid tumours were recruited across 15 centers in Australia and South Korea from October 2018 to August 2021.
Study:
NCT04074759
Study Brief:
Results Section:
NCT04074759